Smith, Elliot H.
Merricks, Edward M.
Liou, Jyun-You
Casadei, Camilla
Melloni, Lucia
Thesen, Thomas
Friedman, Daniel J.
Doyle, Werner K.
Emerson, Ronald G.
Goodman, Robert R.
McKhann, Guy M. II
Sheth, Sameer A.
Rolston, John D.
Schevon, Catherine A.
Funding for this research was provided by:
National Institutes of Health (S10 OD018211, R21 NS113031)
Article History
Received: 6 July 2020
Accepted: 23 October 2020
First Online: 5 November 2020
Competing interests
: Dr. Rolston reports personal fees from Medtronic, personal fees from NeuroPace, Dr. Friedman reports grants, non-financial support and other from Epilepsy Study Consortium, personal fees and other from Eisai, personal fees from Penumbra, grants, personal fees and other from Neuropace, grants from Epitel, grants and other from Empatica, grants and personal fees from UCB, Inc, other from Acorda Pharmaceuticals, grants and other from Adamas Pharmaceuticals, other from Alexza, other from Axcella, other from Biogen, other from Biopharm, other from CuroNZ, other from Engage, other from GW Pharma, other from Pfizer, other from Pfizer-Neusentis, other from Marinus, other from SK Life Sciences, other from Upsher Smith, other from Zogenix, other from Zynerba, other from Neuroview Technology, other from Receptor Life Sciences, other from Medtronic, Inc, other from Xenon pharmaceuticals, outside the submitted work; and Dr. Friedman serves on the editorial board of epilepsy.com and is a member of the executive committee of the physician advisory board of the Epilepsy Foundation of America. Dr. McKhann reports personal fees from Koh Young Inc. Dr. Doyle reports non-financial support and other from Neuroview Technology.